Skip to main content

Table 2 PASI response rates and NNT at Week 24 among the overall population

From: Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis

Treatment PASI75 PASI90
Response (95% CrI) NNT (95% CrI) Response (95% CrI) NNT (95% CrI)
Placebo 7.6% (5.2%, 10.8%) 2.9% (1.8%, 4.5%)
Adalimumab 72.7% (54.0%, 86.7%) 1.5 (1.3, 2.1) 55.5% (36.0%, 74.3%) 1.9 (1.4, 3.0)
Apremilast 23.9% (14.1%, 36.5%) 6.2 (3.6, 13.3) 12.0% (6.1%, 21.0%) 11.0 (5.7, 26.5)
Certolizumab pegol 45.6% (31.6%, 60.4%) 2.6 (1.9, 4.0) 28.4% (17.4%, 42.1%) 3.9 (2.6, 6.7)
Etanercept 26.0% (12.9%, 44.1%) 5.5 (2.8, 16.7) 13.4% (5.5%, 27.1%) 9.6 (4.2, 34.1)
Golimumab 74.1% (56.1%, 87.7%) 1.5 (1.3, 2.0) 57.2% (37.9%, 75.8%) 1.8 (1.4, 2.8)
Infliximab 77.1% (60.5%, 89.5%) 1.4 (1.2, 1.9) 61.0% (42.4%, 78.8%) 1.7 (1.3, 2.5)
Secukinumab 150 mg 50.3% (36.1%, 65.3%) 2.3 (1.8, 3.4) 32.4% (20.6%, 47.2%) 3.4 (2.3, 5.5)
Secukinumab 300 mg 60.4% (39.7%, 79.2%) 1.9 (1.4, 3.0) 42.3% (23.6%, 63.7%) 2.5 (1.7, 4.8)
Ustekinumab 45 mg 51.2% (37.5%, 64.8%) 2.3 (1.8, 3.2) 33.2% (21.8%, 46.6%) 3.3 (2.3, 5.1)
Ustekinumab 90 mg 58.2% (44.7%, 70.8%) 2.0 (1.6, 2.6) 39.9% (27.5%, 53.4%) 2.7 (2.0, 4.0)
  1. CrI credible interval, NNT number needed to treat